Efficacy and Safety Study of Neu2000KWL for Acute Ischemic Stroke Patients Within 6 Hours of Onset

A Phase II, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of the Salfaprodil for Injection in Patients With Acute Ischemic Stroke

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04486430

Acronym

Salfaprodil

Enrollment

236

Registered

2020-07-24

Start date

2017-03-02

Completion date

2019-12-13

Last updated

2020-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Infarction, Stroke

Keywords

Stroke, the Salfaprodil for injection, Neu2000KWL, Neuroprotection, glutamate, free radical

Brief summary

The purpose of the study is to explore safety and efficacy of Salfaprodil administration for patients with acute ischemic stroke within 6 hours of onset.

Detailed description

The present study is to investigate safety and efficacy of Neu2000, a multi-target neuroprotectant acting as a moderate NR2B-selective NMDA receptor antagonist and potent antioxidant, in acute ischemic stroke patients within 6 hours of onset. Compared to NMDA antagonists or antioxidants, improved efficacy and therapeutic time window of Neu2000 have been well documented in four animal models of stroke. Notable Safety of Neu2000 has been demonstrated in 168 human subjects conducted in the US and China as well as animals. In the present phase II study, patients with acute ischemic stroke within 6 hours of onset would be assigned randomly to one of four groups as follows: * Group A receiving 2.75g Neu2000KWL for 5 days * Group B receiving 5.25g Neu2000KWL for 5 days * Group C receiving 6.00g Neu2000KWL for 5 days * Group D receiving placebo for 5 days Patients will receive intravenous infusion of the clinical study drug twice a day at 12±1 hour intervals for 5 days.

Interventions

DRUGNeu2000KWL

1st infusion of 500mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 250 mg at intervals of 12 hours

DRUGPlacebos

1st infusion of the same volume of saline in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of the same volume of saline at intervals of 12 hours

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Masking description

Double Blind

Eligibility

Sex/Gender

ALL

Age

35 Years to 75 Years

Healthy volunteers

Inclusion criteria

1. patients aged between 35 and 75 years; 2. acute ischemic stroke patients in internal carotid artery system within 6 hours of onset; 3. patients with NIHSS scores of 4 to 22 and limb weakness including motor arm or motor leg score ≥2 of NIHSS; 4. patients within 6 hours of onset or the last time known to be symptom free (within 6 hours of the start of sleep for ischemic stroke patients with onset during sleep), and who receive a CT test before the clinical study; 5. Informed consent should be signed from the patient or patient's legally authorized representative; 6. patients with premorbid mRS score of 0\ 1; 7. patients with no history of myocardial infarction within last 3 months; 8. patients with no heart, liver, kidney and lung function deficit; 9. patients with no hemorrhagic diseases within last 3 months; 10. patients with no haematological diseases.

Exclusion criteria

1. Any contraindication to CT and MRI (e.g., metal implants such as pacemakers, claustrophobia); 2. Stroke caused by posterior circulation ischemia, or transient ischemic attack (TIA); 3. Acute intracranial hemorrhage, intracranial neoplasm, cobweb hemorrhage, cerebritis or other non-acute ischemic stroke and cerebral arteriovenous malformation; 4. Endovascular treatment within 6 hours of onset, such as mechanical embolectomy, stent angioplasty or arteriovenous bridge treatment; 5. Pregnant or lactating women. Note: the pregnancy test of fertile women must be negative before randomization into groups, and female patients must take appropriate contraceptive methods at least for 3 weeks prior to the clinical study and over the next 7 days following the last injection of test drugs; 6. Pre-existing medical, neurologic, or psychiatric diseases that would confound the neurologic, functional, or imaging evaluations, such as persistent deficit from previous ischemic stroke; 7. Malignant tumor or other critical disease; 8. Patients with a history of epilepsy or undergoing seizure on onset of the ischemic stroke 9. A history of intracranial hemorrhage; 10. Patients with low blood pressure, or showing blood pressure lower than 90/60mmHg in three consecutive times after admission; 11. A history of severe injury and surgical operation within the last 3 months; 12. Consciousness disorder as defined as NIHSS Ia score ≥2 ; 13. Complete atrioventricular block bradycardia; 14. Cardiac function rating above II level according to the New York heart association (NYHA) grade of cardiac function, history of congestive heart failure (CHF); 15. With primary liver and kidney disease, AST or ALT 2 times greater than upper normal limit, serum creatinine \>2.0 mg/dL or \>176.8 µmol/L; 16. International normalized ratio (INR) \> 1.7 or current use of oral anticoagulants, except aspirin, clopidogrel, subcutaneous heparin or warfarin; 17. With bleeding tendency disease (such as hemophilia), partial thromboplastin time (PTT) \> 3 ×the upper limit of normal; 18. A history of, or known current problems with, drug or alcohol abuse; 19. A irritability experience of the study drugs or drugs with similar chemical structures; 20. Participation in other clinical trials or studies before this study within the last 3 months; 21. Researchers consider that patients don't suit for the study. 22. Hepatitis B and C, HIV-positive patients Imaging

Design outcomes

Primary

Measure	Time frame	Description
The ratio of patients with NIHSS score of 0-1 or with reduction of NIHSS score of ≥4 than the baseline on 14 ± 2 day following the first injection.	days:14±2	The ratio of patients with NIHSS score of 0-1 or with reduction of NIHSS score of ≥4 than the baseline on 14 ± 2 day following the first injection.

Secondary

Measure	Time frame	Description
Change from the baseline in NIHSS score on 14 ± 2, 30 ± 2 and 90 ± 7 days following the first injection. 1. Change from the baseline in NIHSS score on 14 ± 2, 30 ± 2 and 90 ± 7 days following the first injection.	days 14±2, 30±2 and 90±7	Change from the baseline in NIHSS score on 14 ± 2, 30 ± 2 and 90 ± 7 days following the first injection.
Change from the baseline in mRS score on 14 ± 2, 30 ± 2 and 90 ± 7 days following the first injection.	days 14±2, 30±2 and 90±7	Change from the baseline in mRS score on 14 ± 2, 30 ± 2 and 90 ± 7 days following the first injection.
Change from the baseline in Barthel Index (BI) score on 14 ± 2, 30 ± 2 and 90 ± 7 days following the first injection.	days 14±2, 30±2 and 90±7	Change from the baseline in Barthel Index (BI) score on 14 ± 2, 30 ± 2 and 90 ± 7 days following the first injection.

Other

Measure	Time frame	Description
Exploratory Imaging Analysis for Infarct Measurement	day 6±1	Change in infarct volume of the patient measured with MRI prior to the first injection of Neu2000KWL (baseline) and 6 ± 1 day following the first injection.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026